Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).

Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.

Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.

AgomAb Therapeutics NV (‘AgomAb’) announced today the appointment of two new members to its senior team to further strengthen the company’s clinical, legal and corporate development capabilities. Ellen Lefever will join AgomAb as General Counsel, bringing extensive legal and transaction experience in the biotech industry.

AgomAb Therapeutics N.V. (‘AgomAb’) announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.